BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Stocks Fed'. (Return)

MarketWatch MarketPulseAug 05, 2020
Bristol-Myers, Pfizer stocks rise on blood-thinner patent win
Bristol-Myers Squibb Co. shares rallied in the extended session Wednesday after a federal judge ruled for it and Pfizer Inc. in a key patent fight over a blood thinner. Bristol-Myers shares surged 4.4% after hours, following a 0.4% rise to close at $59.69. Pfizer shares advanced 1.5% after hours, following a 0.2% gain to close at $38.45. In a ruling Wednesday, a federal judge said that products made by Sigmapharm Laboratories LLC, Sunshine Lake Pharma Co., and Unichem Laboratories Ltd. infringed patents protecting the blood-thinner Eliquis,, which is generically known as apixaban. Bristol-Myers and Pfizer have a profit-sharing agreement on the drug. "While subject to appeal, at present the generic manufacturers currently involved in the case cannot launch their apixaban products until 2031," said a Bristol-Myers Squibb spokewoman in emailed comments. "Based on settlement agreements reached with other generic manufacturers, we currently expect generic entry could occur after 2026 but before 2031, subject to appeals and future challenges." In 2019, Eliquis was Bristol-Myers's top-selling drug with sales of $2.03 billion, following its acquisition of Celgene in November.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.


TRENDING TAGS
TrumpFacebook Post Coronavirus Biden Children
CoronavirusVaccine Trump Facebook Post latest
earningsCall Transcript Q2 Inc Corp
FacebookTrump Post TikTok Launches Children
StockEarnings market Today gold rise
CallEarnings Transcript Q2 Inc Corp
TikTokFacebook Launches Reels Instagram Users
TranscriptEarnings Call Q2 Inc Corp
Covid-19Vaccine App Apple Google Future
MarketStock gold updates Investors earnings

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC